Pharmaceutical Supply Chains

Medicine supply involves more than manufacturing a finished product. Iranian research distinguishes financing, purchasing and importing, domestic production, storage and distribution, and problems experienced by patients. These connected activities help explain why a manufacturing sector can coexist with difficulty obtaining particular medicines. s1

A qualitative study based on interviews conducted in 2019 identified reported banking barriers, foreign-currency constraints, customs delays, and weaknesses in estimating demand. Participants also described dependence on imported production inputs. These accounts explain potential points of disruption; they do not measure national shortage rates or establish the condition of every medicine supply route. s1

[s1]

The same study recorded concerns about domestic administrative coordination, distribution oversight, and incentives surrounding medicine supply. Its evidence therefore does not support treating every shortage as the result of one external factor. Import arrangements, manufacturing inputs, and domestic financing can interact. Because the findings are interview-based, allegations about misconduct should be understood as participants’ reports rather than independently established findings about particular companies. s1

A separate study, published in 2021 using interviews conducted in 2018, explored ways to strengthen supply resilience. Participants proposed better coordination among manufacturers, distributors, prescribers, and insurers, alongside improved information systems and purchasing arrangements. In this context, resilience means the ability to withstand disruption and adapt supply arrangements. The study offers stakeholder proposals, not proof that the proposed measures were implemented or succeeded. s2

[s1] [s2]

Research published in July 2026 examines Darooyar, Iran’s pharmaceutical subsidy reform. The authors describe its intended shift from subsidized foreign-exchange allocation toward support through insurance coverage. That distinction matters: changing where a subsidy enters the system also changes which organizations must finance purchases and reimburse costs. s3

Interviewees reported unstable funding, delayed reimbursements, and liquidity shortages across the supply chain. Liquidity here means access to funds needed to meet immediate obligations. They also identified fragmented responsibilities and inadequate monitoring systems. Some perceived improvements in insurance coverage and reduced outward medicine smuggling, but these were qualitative findings rather than measured national effects. The study supports examining implementation alongside policy design. s3

[s3]

Taken together, these studies connect physical medicine supply with payments, information, and institutional coordination. They support asking where a disruption occurs and whose obligations remain unmet, rather than assuming that increasing production alone resolves access problems. Their methods, however, cannot establish a continuous national timeline of medicine availability. s1s2s3

For international readers, the central distinction is between a documented mechanism and its measured scale. The inspected research provides detailed stakeholder accounts of mechanisms. It does not provide comparable annual observations showing how many patients, pharmacies, or products were affected across Iran. National totals and provincial comparisons therefore remain outside this account. s1s3

[s1] [s2] [s3]